I quote from Sierra's note in #2153 about talking
Post# of 9122
Posted On: 02/25/2016 2:18:48 PM
I quote from Sierra's note in #2153 about talking to the NanoLogix CEO.
"Called NNLX and talked to BB...said flatpack sales are enough for them to cover expenses and that flatpack sales are increasing."
There is a powerful dynamic developing here that oddly enough helps rather than hurts "longs" at this point because it means we can buy more shares at a very cheap and unrealistic price. The two most important factors are 1. that the Battelle Flatpack paper came out just at the end of 2015, and 2. that sales are increasing steadily since then to the point that they cover, and perhaps more than cover operating expenses.
Why are these two factors important? First of all, institutions using petri plates, including ones designed for specific purposes, need to know that the product has been validated through serious scientific research and testing. It is not enough for such legitimate institutions to take a producer's representation that its product is the "best thing since sliced bread" because we know that companies lie and hype all the time and that small companies do it even more. Now for the past two months or so since the Flatback has been validated it is no surprise that the sales are increasing substantially. Given the indication that revenues have now met or even exceeded operating costs and that the trend is likely to be rapidly upward it is probable that NanoLogix can begin banking revenues.
This means that as revenues increase just from the Flatpack sales that there is no need to raise new investor funds and it also means that while the share price can be a short term irritant for longs it also represents an opportunity to obtain more shares at a low "bargain" price. As sales revenue increase and are banked it can also mean that at some point we could see the Company beginning to do share buybacks that reduce the marketable share volume and increase per share price.
And this is something entirely independent of added revenues that can be expected from the N-Assay whether from sales or a significant licensing or buyout deal with a major medical supplies company seeking to devastate competitors with the long life and customized petri plate Flatpack or N-Assay complex multi-faceted diagnostic sector. It is truly a fascinating moment and it seems that things will be playing out positively for "longs" and negatively for "bashers" over the next months.
"Called NNLX and talked to BB...said flatpack sales are enough for them to cover expenses and that flatpack sales are increasing."
There is a powerful dynamic developing here that oddly enough helps rather than hurts "longs" at this point because it means we can buy more shares at a very cheap and unrealistic price. The two most important factors are 1. that the Battelle Flatpack paper came out just at the end of 2015, and 2. that sales are increasing steadily since then to the point that they cover, and perhaps more than cover operating expenses.
Why are these two factors important? First of all, institutions using petri plates, including ones designed for specific purposes, need to know that the product has been validated through serious scientific research and testing. It is not enough for such legitimate institutions to take a producer's representation that its product is the "best thing since sliced bread" because we know that companies lie and hype all the time and that small companies do it even more. Now for the past two months or so since the Flatback has been validated it is no surprise that the sales are increasing substantially. Given the indication that revenues have now met or even exceeded operating costs and that the trend is likely to be rapidly upward it is probable that NanoLogix can begin banking revenues.
This means that as revenues increase just from the Flatpack sales that there is no need to raise new investor funds and it also means that while the share price can be a short term irritant for longs it also represents an opportunity to obtain more shares at a low "bargain" price. As sales revenue increase and are banked it can also mean that at some point we could see the Company beginning to do share buybacks that reduce the marketable share volume and increase per share price.
And this is something entirely independent of added revenues that can be expected from the N-Assay whether from sales or a significant licensing or buyout deal with a major medical supplies company seeking to devastate competitors with the long life and customized petri plate Flatpack or N-Assay complex multi-faceted diagnostic sector. It is truly a fascinating moment and it seems that things will be playing out positively for "longs" and negatively for "bashers" over the next months.
(5)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼